BRAIN and NERVE－神経研究の進歩67巻11号

2015年11月発行

記事購入ページに移動

増大特集 ギラン・バレー症候群のすべて—100年の軌跡

ギラン・バレー症候群の自己抗体

著者： 内堀歩¹ 千葉厚郎¹

所属機関： ¹杏林大学神経内科

ページ範囲：P.1347 - P.1357

ギラン・バレー症候群ではガングリオシドを中心とする糖脂質に対する抗体が約60%で検出される。抗体価は急性期に最も高く，経過とともに低下する。臨床病型と検出される抗体の種類には一定の対応傾向がある。末梢神経組織におけるガングリオシドの局在，先行感染病原体における分子相同性糖鎖構造の証明，ガングリオシド感作動物モデルの作製などの検討により，糖脂質抗体による補体介在性の神経組織障害機序が推測されている。

参考文献

1) Melnick SC: Thirty-eight cases of the Guillain-Barré syndrome: an immunological study. Br Med J 1: 368-373, 1963

2) Saida T, Saida K, Silberberg DH, Brown MJ: Experimental allergic neuritis induced by galactocerebroside. Ann Neurol 9: 87-101, 1981

3) Saida K, Saida T: Proliferation of Schwann cells in demyelinated rat sciatic nerve. Acta Neuropathol 71: 251-258, 1986

4) Ilyas AA, Quarles RH, MacIntosh TD, Dobersen MJ, Trapp BD, et al: IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci U S A 81: 1225-1229, 1984

5) Ilyas AA, Dalakas MC, Brady RO, Quarles RH: Sulfated glucuronyl glycolipids reacting with anti-myelin-associated glycoprotein monoclonal antibodies including IgM paraproteins in neuropathy: species distribution and partial characterization of epitopes. Brain Res 385: 1-9, 1986

6) Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, et al: Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 23: 440-447, 1988

7) Willison HJ, Yuki N: Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591-2625, 2002

8) Kaida K, Ariga T, Yu RK: Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders: a review. Glycobiology 19: 676-692, 2009

9) Uncini A, Susuki K, Yuki N: Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol 124: 1928-1934, 2013

10) Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I: Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 43: 1911-1917, 1993

11) Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I: Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 745: 32-36, 1997

12) Lopez PH, Schnaar RL: Gangliosides in cell recognition and membrane protein regulation. Curr Opin Struct Biol 19: 549-557, 2009

13) Sheikh KA, Deerinck TJ, Ellisman MH, Griffin JW: The distribution of ganglioside-like moieties in peripheral nerves. Brain 122: 449-460, 1999

14) Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, et al: Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 8: 48-58, 2011

15) Hughes RA, Hadden RD, Gregson NA, Smith KJ: Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 100: 74-97, 1999

16) Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, et al: A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med 178: 1771-1775, 1993

17) Yuki N, Yamada M, Koga M, Odaka M, Susuki K, et al: Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49: 712-720, 2001

18) Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, et al: Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 27: 3956-3967, 2007

channel current is inhibited by serum from select patients with Guillain-Barré syndrome. Neurochem Res 34: 149-157, 2009

20) Kusunoki S, Chiba A, Tai T, Kanazawa I: Localization of GM1 and GD1b antigens in the human peripheral nervous system. Muscle Nerve 16: 752-756, 1993

21) Kusunoki S, Mashiko H, Mochizuki N, Chiba A, Arita M, et al: Binding of antibodies against GM1 and GD1b in human peripheral nerve. Muscle Nerve 20: 840-845, 1997

22) Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, et al: Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 39: 424-431, 1996

23) Susuki K, Yuki N, Schafer DP, Hirata K, Zhang G, et al: Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233: 534-542, 2012

24) Willison HJ, O'Leary CP, Veitch J, Blumhardt LD, Busby M, et al: The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124: 1968-1977, 2001

25) Oka N, Kusaka H, Kusunoki S, Tsuda H, Kaji R, et al: IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons. Muscle Nerve 19: 528-530, 1996

26) Ohsawa T, Miyatake T, Yuki N: Anti-B-series ganglioside-recognizing autoantibodies in an acute sensory neuropathy patient cause cell death of rat dorsal root ganglion neurons. Neurosci Lett 157: 167-170, 1993

27) Koga M, Tatsumoto M, Yuki N, Hirata K: Range of cross reactivity of anti-GM1 IgG antibody in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 71: 123-124, 2001

28) Susuki K, Yuki N, Hirata K: Fine specificity of anti-GQ1b IgG and clinical features. J Neurol Sci 185: 5-9, 2001

29) Mizoguchi K, Hase A, Obi T, Matsuoka H, Takatsu M, et al: Two species of antiganglioside antibodies in a patient with a pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 57: 1121-1123, 1994

30) Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, et al: Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118: 597-605, 1995

31) Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, et al: Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48: 624-631, 2000

32) Gong Y, Tagawa Y, Lunn MP, Laroy W, Heffer-Lauc M, et al: Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 125: 2491-2506, 2002

33) Lopez PH, Zhang G, Bianchet MA, Schnaar RL, Sheikh KA: Structural requirements of anti-GD1a antibodies determine their target specificity. Brain 131: 1926-1939, 2008

34) Buchwald B, Zhang G, Vogt-Eisele AK, Zhang W, Ahangari R, et al: Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol Dis 28: 113-121, 2007

35) Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I: GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody. Neurology 61: 465-470, 2003

36) Nakatani Y, Nagaoka T, Hotta S, Utsunomiya I, Yoshino H, et al: IgG anti-GalNAc-GD1a antibody inhibits the voltage-dependent calcium channel currents in PC12 pheochromocytoma cells. Exp Neurol 204: 380-386, 2007

37) Odaka M, Yuki N, Tatsumoto M, Tateno M, Hirata K: Ataxic Guillain-Barré syndrome associated with anti-GM1b and anti-GalNAc-GD1a antibodies. J Neurol 251: 24-29, 2004

38) Jacobs BC, Rothbarth PH, van der Meché FG, Herbrink P, Schmitz PI, et al: The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51: 1110-1115, 1998

39) Koga M, Yuki N, Tai T, Hirata K: Miller Fisher syndrome and Haemophilus influenzae infection. Neurology 57: 686-691, 2001

40) Ang CW, Laman JD, Willison HJ, Wagner ER, Endtz HP, et al: Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients. Infect Immun 70: 1202-1208, 2002

41) Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, et al: Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 101: 11404-11409, 2004

42) Khalili-Shirazi A, Gregson N, Gray I, Rees J, Winer J, et al: Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry 66: 376-379, 1999

43) Kaida K, Kusunoki S, Kamakura K, Motoyoshi K, Kanazawa I: Guillain-Barré syndrome with IgM antibody to the ganglioside GalNAc-GD1a. J Neuroimmunol 113: 260-267, 2001

44) Ang CW, Jacobs BC, Brandenburg AH, Laman JD, van der Meché FG, et al: Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome. Neurology 54: 1453-1458, 2000

45) Kusunoki S, Shiina M, Kanazawa I: Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 57: 736-738, 2001

46) Mori M, Kuwabara S, Miyake M, Noda M, Kuroki H, et al: Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 123: 2171-2178, 2000

47) Mori M, Kuwabara S, Miyake M, Dezawa M, Adachi-Usami E, et al: Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome. Neurology 52: 1282-1284, 1999

48) Kusunoki S, Morita D, Ohminami S, Hitoshi S, Kanazawa I: Binding of immunoglobulin G antibodies in Guillain-Barré syndrome sera to a mixture of GM1 and a phospholipid: possible clinical implications. Muscle Nerve 27: 302-306, 2003

49) Dykstra M, Cherukuri A, Sohn HW, Tzeng SJ, Pierce SK: Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol 21: 457-481, 2003

50) Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, et al: Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol 56: 567-571, 2004

51) Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, et al: Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 182: 212-218, 2007

52) Kaida K, Morita D, Kanzaki M, Kamakura K, Motoyoshi K, et al: Anti-ganglioside complex antibodies in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 77: 1043-1046, 2006

53) Kanzaki M, Kaida K, Ueda M, Morita D, Hirakawa M, et al: Ganglioside complexes containing GQ1b as targets in Miller Fisher and Guillain-Barré syndromes. J Neurol Neurosurg Psychiatry 79: 1148-1152, 2008

54) Yuki N, Fukami Y, Yanaka C, Koike S, Hirata K: GD1b-specific antibodies may bind to complex of GQ1b and GM1, causing ataxia. J Neurol 261: 1565-1569, 2014

55) Kaida K, Sonoo M, Ogawa G, Kamakura K, Ueda-Sada M, et al: GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barré syndrome. Neurology 71: 1683- 1690, 2008

56) Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, et al: Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 104: 697-708, 1999

57) Halstead SK, O'Hanlon GM, Humphreys PD, Morrison DB, Morgan BP, et al: Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127: 2109-2123, 2004

58) O'Hanlon GM, Humphreys PD, Goldman RS, Halstead SK, Bullens RW, et al: Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain 126: 2497-2509, 2003

59) Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio-Gillen AP, et al: Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome. J Immunol 177: 4211-4217, 2006

60) Ueda A, Shima S, Miyashita T, Ito S, Ueda M, et al: Anti-GM1 antibodies affect the integrity of lipid rafts. Mol Cell Neurosci 45: 355-362, 2010